Elias Arnér and Janne Lehtiö will now represent Karolinska Institutet on the Cancer Core Europe (CCE) board of directors, effective July 2024. They will succeed Jonas Bergh as Karolinska’s representatives in the consortium.
Doctor Elias Arnér
Dr. Arnér is the Director of Cancer Research at KI (CRKI) and previously taught biochemistry. Since 2016, he has served as the Director of Doctoral Studies at Karolinska Institutet, a Medical University.
Elias directs a research group that investigates the role and function of selenoproteins. His research focuses on the mammalian thioredoxin system, specifically the expression, regulation, and function of the selenoprotein thioredoxin reductase 1 (TrxR1) and its splice variants, notably in relation to cellular signaling events and cancer. His study also focuses on the development of selenoprotein manufacturing methods and their potential applications in a wide range of biotechnological fields.
“I am honored to be appointed to the CCE Board of Directors and look forward to contributing to the collaborative efforts in advancing cancer research and treatment. Together with Janne, I am committed to continuing the legacy of excellence established by our predecessor, Prof. Jonas Berg“ said Dr. Elias Arnér.
Professor Janne Lehtiö
Professor Janne Lehtiö and the LehtiöLab study proteomics and proteogenomics to acquire new insights into the molecular phenotype of cancer and apply that knowledge to better customized therapy. Lehtiö has been a principal investigator at Karolinska Institutet (KI) in Sweden since 2008, where he leads a cancer proteomics research team of 25 researchers.
He has been working with CCE and CCE_DART for several years, speaking at CCE Summer Schools and contributing to the CCE Virtual Data Centre (VDC) pillar.
Reflecting in the new appointments, Dr. Josep Tabernero Vall d’Hebron Institute of Oncology (VHIO) Director and CCE’s chairperson, comments “We extend our gratitude to Prof. Jonas Bergh for his dedication and contributions over the last years. We are confident that Elias and Janne will continue with the same commitment and excellence”.
